Related Experiment Videos
[Features of the metabolic activity of the mononuclear phagocytic system in multiple sclerosis patients]
Abstract:
Metabolic activity of the mononuclear phagocytic system (MPS) was studied in 65 patients with disseminated sclerosis (DS) and 65 control persons by determination of the test-substance biotransformation intensity. Sulfadimezine undergoing acetylation in MPS cells was chosen as a test-substance. Sulfadimezine was administered per os; both unchanged drug and its acetylated metabolite were detected in urine in 6 hours. Correlation between acetylated and non-acetylated sulfadimezine levels permitted dividing the examinees into "rapid" or "slow" acetylators (inactivators). Patients with DS belong mainly to slow acetylators since the test-substance in MPS cells of these patients is inactivated slowly. Correlation between "slow" and "rapid" acetylators in patients with DS was 5:1, that in the control group 2:1. A similar pattern was reported previously in patient with systemic lupus erythematosus. New approaches to the mechanisms of DS development based on MPS functions analysis are outlined.
Insights
Patients with disseminated sclerosis (DS) are predominantly slow acetylators, indicating slower metabolic activity in their mononuclear phagocytic system (MPS). This finding suggests a potential link between MPS function and DS development.
Area of Science:
- Immunology
- Pharmacogenetics
- Neuroimmunology
Context:
- Disseminated sclerosis (DS) is a chronic inflammatory disease of the central nervous system.
- The mononuclear phagocytic system (MPS) plays a crucial role in immune responses.
- Individual differences in drug metabolism can impact disease susceptibility and progression.
Purpose:
- To investigate the metabolic activity of the mononuclear phagocytic system (MPS) in patients with disseminated sclerosis (DS).
- To determine if DS patients exhibit distinct patterns of drug metabolism compared to healthy individuals.
- To explore potential new approaches to understanding DS pathogenesis based on MPS function.
Summary:
- This study assessed MPS metabolic activity in 65 DS patients and 65 controls using sulfadimezine biotransformation.
- Individuals were classified as 'rapid' or 'slow' acetylators based on sulfadimezine metabolism.
- DS patients predominantly showed slow acetylation (5:1 ratio) compared to controls (2:1), suggesting impaired MPS inactivation of the test substance.
Impact:
- The findings suggest a significant correlation between slow acetylation, indicative of reduced MPS metabolic activity, and disseminated sclerosis.
- This research opens new avenues for investigating the role of MPS function in the mechanisms underlying DS.
- Understanding these metabolic differences may lead to novel diagnostic or therapeutic strategies for DS.